BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Serabelisib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Serabelisib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06463028-9074@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Serabelisib: Phase 2 readout est. (NCT06463028)
DESCRIPTION:Serabelisib\, phase 2\, Endometrial Cancer.\nStudy: Sapaniserti
 b and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-
 Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/serabelisib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06463028
URL:https://assetmemo.bio/drug/serabelisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558733-9074@assetmemo.bio
DTSTAMP:20261121T004542Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Serabelisib: Phase 1/2 readout est. (NCT07558733)
DESCRIPTION:Serabelisib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Pa
 tients With HR+/HER2- Advanced/Metastatic Breast Cancer\nEstimated primary
  completion: May 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/serabelisib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07558733
URL:https://assetmemo.bio/drug/serabelisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
